BPC-157 and orthopedic recovery
BPC-157 is a synthetic peptide of 15 amino acids, derived from a protein found in stomach fluid. It gets attention for tendon and ligament healing. Here is what is actually known.
What the research found
A 2025 systematic review in HSS Journal searched the literature through June 2024 and included 36 studies. Thirty-five were preclinical, and one was clinical. In rats, BPC-157 was linked to better structure and function in muscle, the Achilles and quadriceps tendons and the medial collateral ligament. In rabbits, it performed about as well as bone grafting in a nonunion model.
The only human study was a retrospective review of 12 patients with chronic knee pain of unspecified cause who received injections into the joint. Seven reported improvement lasting more than six months. The authors call this weak evidence.
What is not known
The review found no clinical safety data. Animal studies ran up to six weeks, so long-term effects are unstudied. Its half-life in the body is under 30 minutes, which raises open questions about how dosing translates to people. Products sold online as research chemicals also carry the quality problems described in our safety guide.
Competitive athletes should know that BPC-157 is prohibited by WADA and several professional leagues.
TB-500 is a second peptide with a comparable evidence gap. The quality problems with research-chemical peptides sold online are covered in our safety guide. For tendon pain, loading comes first whatever else is considered. Status, evidence and risk are explained at a physician consultation, not on a website.
Strength of the evidence
- Early lab and animal research
- Small human studies
- Controlled human trials
- Approved for this use
Early lab and animal research. One small retrospective human report. No controlled human trials in this review.
Regulatory status
- Not FDA-approved for any use.
- In 2023 the FDA placed it in Category 2, a list of substances raising significant safety concerns for compounding. In April 2026 it announced it would remove it, along with 11 other peptides, after the nominations were withdrawn. Removal does not make it eligible for compounding.
- On July 23, 2026, an FDA advisory committee voted 8 to 6 to recommend adding it to the 503A bulks list. The vote is not binding and formal rulemaking is required.
Current as of October 28, 2026. Status is changing. Confirm with the FDA before relying on it. Sources are listed in the safety guide.
References
About the clinical team behind this page
Author
Dr. Angel Williams, PT, DPT, OCS, FAAOMPT
Director of Orthopaedic Rehabilitation & Biomechanical Recovery
Dr. Angel Williams is a board-certified Orthopaedic Clinical Specialist and a Fellow of the American Academy of Orthopaedic Manual Physical Therapists. Dr. Williams has served as a supervising physical therapist at Nova and designs rehabilitation programs built on progressive loading, manual therapy and dry needling for tendon, ligament and post-surgical recovery. Where a physician prescribes a cellular therapy alongside rehabilitation, Dr. Williams builds the loading program that goes with it.
- NPI 1174844872 (CMS registry)
- GA license PT012751, verify with the Georgia State Board of Physical Therapy
- Board-Certified Orthopaedic Clinical Specialist (OCS), American Board of Physical Therapy Specialties (ABPTS)
- Fellow of the American Academy of Orthopaedic Manual Physical Therapists (FAAOMPT)
Dr. Arnaldo Manuel Mora is Medical Director and leads clinical governance at Nova. His background is in internal and occupational medicine. He oversees diagnostic intake, baseline laboratory review and the safety standards that apply before any prescription therapy, including pharmacy sourcing and contraindication screening as described in our safety guide.
Medical disclaimer: The information on this site is for education and does not replace a consultation, diagnosis or treatment. Peptides are prescription-only at Nova, are prescribed only after an in-person physician evaluation, and are not FDA-approved for orthopedic use. Full credentials are on our physicians and clinical governance page.
Keep reading
Individual results vary and no outcome is guaranteed. Peptides discussed on this site are not FDA-approved for orthopedic use, and a physician decides after an in-person evaluation whether any is appropriate.